Date | Price Target | Rating | Analyst |
---|---|---|---|
3/15/2024 | $10.00 | Buy | ROTH MKM |
8/4/2022 | $6.00 | Buy | Ladenburg Thalmann |
WALTHAM, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the presentation of longer-term data from its pivotal trial of cosibelimab, its anti-programmed death ligand-1 ("PD-L1") antibody, in locally advanced and metastatic cutaneous squamous cell carcinoma ("cSCC") during the European Society for Medical Oncology ("ESMO") Congress 2024, which is taking place in Barcelona, Spain, from September 13 to 17, 2024. Poster Presentation Title: Cosibelimab in Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Longer-term Efficacy and Safety Results from Pivotal Study
SCOTTSDALE, Ariz., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or "the Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, President and Chief Executive Officer, will attend one-on-one meetings at the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference, scheduled to take place on Thursday, September 12, 2024 in New York City. About Journey Medical CorporationJourney Medical Corporation (NASD
MIAMI, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference. The presentation will be available for on-demand viewing by conference attendees starting on September 9, 2024, at 7:00 a.m. ET. The Company will also attend one-on-one meetings during the conference. About
4 - Fortress Biotech, Inc. (0001429260) (Issuer)
4 - Fortress Biotech, Inc. (0001429260) (Issuer)
4 - Fortress Biotech, Inc. (0001429260) (Issuer)
New Drug Application for DFD-29 to treat rosacea under FDA review; PDUFA goal date of November 4, 2024 Total revenues for the second quarter ended June 30, 2024 were $14.9 million, a 14% increase from the $13.0 million reported in the first quarter of 2024 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for
SCOTTSDALE, Ariz., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its second quarter 2024 financial results after the U.S. financial markets close on Monday, August 12, 2024. Journey Medical management will conduct a conference call and audio webcast on Monday, August 12, 2024 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic)
MIAMI, July 25, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress", or the "Company"), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced that it has entered into a new loan agreement (the "Agreement") for up to $50 million with funds managed by Oaktree Capital Management, L.P. ("Oaktree"). The Company will receive an initial tranche of $35 million and is eligible to draw an additional $15 million at Oaktree's discretion to support future business development activities. In connection with the new loan a
HC Wainwright & Co. analyst Joseph Pantginis reiterates Fortress Biotech (NASDAQ:FBIO) with a Buy and maintains $24 price target.
- SEC Filing
Collaboration explores the potential synergistic effects of Checkpoint's anti-PD-L1, cosibelimab, in combination with the autologous T cell therapy, Immuncell-LC
10-Q - Fortress Biotech, Inc. (0001429260) (Filer)
8-K - Fortress Biotech, Inc. (0001429260) (Filer)
424B5 - Fortress Biotech, Inc. (0001429260) (Filer)
ROTH MKM resumed coverage of Fortress Biotech with a rating of Buy and set a new price target of $10.00
Ladenburg Thalmann initiated coverage of Fortress Biotech with a rating of Buy and set a new price target of $6.00
Roth Capital reiterated coverage of Fortress Biotech with a rating of Buy and set a new price target of $5.00 from $4.50 previously
SCOTTSDALE, Ariz., July 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that on July 9, 2024, it appointed Michael C. Pearce to its Board of Directors. Mr. Pearce is a principal investor with an emphasis on healthcare. Since 2015, he has served as an advisor to EP Group and board member of its predecessor parent company, Evening Post Industries ("EPI"). At EPI, he served on the audit, compensation, and inves
SCOTTSDALE, Ariz., May 01, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or "the Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the appointment of Joseph M. Benesch as Chief Financial Officer, effective April 26, 2024. Mr. Benesch had served as the Company's Interim Chief Financial Officer since January 2023 and he served as the Company's Corporate Controller prior to that since November 2021. Claude Maraoui, Co-Founder, President and Chief
WALTHAM, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the appointment of Amit Sharma, M.D., FACP, FASN, FNKF, to its Board as an independent, non-executive director, effective immediately. Dr. Sharma currently serves as Vice President of Clinical Development and Therapeutic Head for Nephrology and Hematology at Alexion, AstraZeneca Rare Disease, where he guides and executes the strategic direction of development products and programs within Alexion's nephrology franchise across all stages of development. Prior to joining Alexion, he served as Vice Presiden
4 - Fortress Biotech, Inc. (0001429260) (Issuer)
4 - Fortress Biotech, Inc. (0001429260) (Issuer)
4 - Fortress Biotech, Inc. (0001429260) (Issuer)
SC 13G/A - Fortress Biotech, Inc. (0001429260) (Subject)
SC 13D/A - Fortress Biotech, Inc. (0001429260) (Subject)
SC 13D/A - Fortress Biotech, Inc. (0001429260) (Subject)